Review



ot ii  (Jackson Laboratory)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Jackson Laboratory ot ii
    OV-BYTE strategy boosts systemic pathogen-specific CD4 + T MEM cell responses (A) Schematic of the experimental design. Congenic CD45.1 + SM CD4 + T cells were adoptively transferred into <t>naive</t> <t>C57BL/6</t> recipients (CD45.2 + ), which were then infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, SM CD4 + T cells in various organs were analyzed. (B and C) Frequency (B) and number (C) of SM CD4 + cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). Quantification of SM CD4 + cells from 100 μL of peripheral blood. (D) Flow cytometry analysis of SM CD4 + T cells on day 15 post-tumor engraftment from the PBS-, NDV-WT-, or NDV-GP-treated group. Numbers adjacent to the outlined areas indicates percentages of SM CD4 + cells among total CD4 + T cells. (E) Schematic of the experimental design. Naive C57BL/6 mice were infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, endogenous LCMV GP 66-77 tetramer + CD4 + T cells in various organs were analyzed. (F and G) Frequency (F) and number (G) of endogenous LCMV GP 66-77 tetramer + CD4 + T cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). (H) Schematic of the experimental design. Congenic CD45.1 <t>+</t> <t>OT-II</t> CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LM-OVA and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, Ad5-WT, or Ad5-OVA daily via the intratumoral route. On day 15 post-tumor engraftment, OT-II CD4 + T cells in various organs were analyzed. (I and J) Frequency (I) and number (J) of OT-II CD4 + cells in the indicated organs of groups administrated PBS (indicated by gray dots), Ad5-WT (indicated by blue dots), or Ad5-OVA (indicated by red dots). All data are representative of at least two independent experiments with at least four mice per group. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA with Turkey’s test (B, C, F, G, I, J). Center values and error bars (B, C, F, G, I, J) indicate mean and SEM.
    Ot Ii, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ot+ii/pmc13122683-247-1-15?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    ot ii - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "Oncolytic virotherapy mobilizes tumor-resident, granzyme B-producing bystander CD4 + T cells to inhibit systemic microbial infection"

    Article Title: Oncolytic virotherapy mobilizes tumor-resident, granzyme B-producing bystander CD4 + T cells to inhibit systemic microbial infection

    Journal: Molecular Therapy Oncology

    doi: 10.1016/j.omton.2026.201187

    OV-BYTE strategy boosts systemic pathogen-specific CD4 + T MEM cell responses (A) Schematic of the experimental design. Congenic CD45.1 + SM CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, SM CD4 + T cells in various organs were analyzed. (B and C) Frequency (B) and number (C) of SM CD4 + cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). Quantification of SM CD4 + cells from 100 μL of peripheral blood. (D) Flow cytometry analysis of SM CD4 + T cells on day 15 post-tumor engraftment from the PBS-, NDV-WT-, or NDV-GP-treated group. Numbers adjacent to the outlined areas indicates percentages of SM CD4 + cells among total CD4 + T cells. (E) Schematic of the experimental design. Naive C57BL/6 mice were infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, endogenous LCMV GP 66-77 tetramer + CD4 + T cells in various organs were analyzed. (F and G) Frequency (F) and number (G) of endogenous LCMV GP 66-77 tetramer + CD4 + T cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). (H) Schematic of the experimental design. Congenic CD45.1 + OT-II CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LM-OVA and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, Ad5-WT, or Ad5-OVA daily via the intratumoral route. On day 15 post-tumor engraftment, OT-II CD4 + T cells in various organs were analyzed. (I and J) Frequency (I) and number (J) of OT-II CD4 + cells in the indicated organs of groups administrated PBS (indicated by gray dots), Ad5-WT (indicated by blue dots), or Ad5-OVA (indicated by red dots). All data are representative of at least two independent experiments with at least four mice per group. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA with Turkey’s test (B, C, F, G, I, J). Center values and error bars (B, C, F, G, I, J) indicate mean and SEM.
    Figure Legend Snippet: OV-BYTE strategy boosts systemic pathogen-specific CD4 + T MEM cell responses (A) Schematic of the experimental design. Congenic CD45.1 + SM CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, SM CD4 + T cells in various organs were analyzed. (B and C) Frequency (B) and number (C) of SM CD4 + cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). Quantification of SM CD4 + cells from 100 μL of peripheral blood. (D) Flow cytometry analysis of SM CD4 + T cells on day 15 post-tumor engraftment from the PBS-, NDV-WT-, or NDV-GP-treated group. Numbers adjacent to the outlined areas indicates percentages of SM CD4 + cells among total CD4 + T cells. (E) Schematic of the experimental design. Naive C57BL/6 mice were infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, endogenous LCMV GP 66-77 tetramer + CD4 + T cells in various organs were analyzed. (F and G) Frequency (F) and number (G) of endogenous LCMV GP 66-77 tetramer + CD4 + T cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). (H) Schematic of the experimental design. Congenic CD45.1 + OT-II CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LM-OVA and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, Ad5-WT, or Ad5-OVA daily via the intratumoral route. On day 15 post-tumor engraftment, OT-II CD4 + T cells in various organs were analyzed. (I and J) Frequency (I) and number (J) of OT-II CD4 + cells in the indicated organs of groups administrated PBS (indicated by gray dots), Ad5-WT (indicated by blue dots), or Ad5-OVA (indicated by red dots). All data are representative of at least two independent experiments with at least four mice per group. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA with Turkey’s test (B, C, F, G, I, J). Center values and error bars (B, C, F, G, I, J) indicate mean and SEM.

    Techniques Used: Infection, Flow Cytometry



    Similar Products

    ot ii  (Jackson Laboratory)
    86
    Jackson Laboratory ot ii
    OV-BYTE strategy boosts systemic pathogen-specific CD4 + T MEM cell responses (A) Schematic of the experimental design. Congenic CD45.1 + SM CD4 + T cells were adoptively transferred into <t>naive</t> <t>C57BL/6</t> recipients (CD45.2 + ), which were then infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, SM CD4 + T cells in various organs were analyzed. (B and C) Frequency (B) and number (C) of SM CD4 + cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). Quantification of SM CD4 + cells from 100 μL of peripheral blood. (D) Flow cytometry analysis of SM CD4 + T cells on day 15 post-tumor engraftment from the PBS-, NDV-WT-, or NDV-GP-treated group. Numbers adjacent to the outlined areas indicates percentages of SM CD4 + cells among total CD4 + T cells. (E) Schematic of the experimental design. Naive C57BL/6 mice were infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, endogenous LCMV GP 66-77 tetramer + CD4 + T cells in various organs were analyzed. (F and G) Frequency (F) and number (G) of endogenous LCMV GP 66-77 tetramer + CD4 + T cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). (H) Schematic of the experimental design. Congenic CD45.1 <t>+</t> <t>OT-II</t> CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LM-OVA and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, Ad5-WT, or Ad5-OVA daily via the intratumoral route. On day 15 post-tumor engraftment, OT-II CD4 + T cells in various organs were analyzed. (I and J) Frequency (I) and number (J) of OT-II CD4 + cells in the indicated organs of groups administrated PBS (indicated by gray dots), Ad5-WT (indicated by blue dots), or Ad5-OVA (indicated by red dots). All data are representative of at least two independent experiments with at least four mice per group. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA with Turkey’s test (B, C, F, G, I, J). Center values and error bars (B, C, F, G, I, J) indicate mean and SEM.
    Ot Ii, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ot+ii/pmc13122683-247-1-15?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    ot ii - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    ot ii mice  (Jackson Laboratory)
    86
    Jackson Laboratory ot ii mice
    OV-BYTE strategy boosts systemic pathogen-specific CD4 + T MEM cell responses (A) Schematic of the experimental design. Congenic CD45.1 + SM CD4 + T cells were adoptively transferred into <t>naive</t> <t>C57BL/6</t> recipients (CD45.2 + ), which were then infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, SM CD4 + T cells in various organs were analyzed. (B and C) Frequency (B) and number (C) of SM CD4 + cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). Quantification of SM CD4 + cells from 100 μL of peripheral blood. (D) Flow cytometry analysis of SM CD4 + T cells on day 15 post-tumor engraftment from the PBS-, NDV-WT-, or NDV-GP-treated group. Numbers adjacent to the outlined areas indicates percentages of SM CD4 + cells among total CD4 + T cells. (E) Schematic of the experimental design. Naive C57BL/6 mice were infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, endogenous LCMV GP 66-77 tetramer + CD4 + T cells in various organs were analyzed. (F and G) Frequency (F) and number (G) of endogenous LCMV GP 66-77 tetramer + CD4 + T cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). (H) Schematic of the experimental design. Congenic CD45.1 <t>+</t> <t>OT-II</t> CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LM-OVA and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, Ad5-WT, or Ad5-OVA daily via the intratumoral route. On day 15 post-tumor engraftment, OT-II CD4 + T cells in various organs were analyzed. (I and J) Frequency (I) and number (J) of OT-II CD4 + cells in the indicated organs of groups administrated PBS (indicated by gray dots), Ad5-WT (indicated by blue dots), or Ad5-OVA (indicated by red dots). All data are representative of at least two independent experiments with at least four mice per group. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA with Turkey’s test (B, C, F, G, I, J). Center values and error bars (B, C, F, G, I, J) indicate mean and SEM.
    Ot Ii Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ot+ii/pm42270933-55-5-11?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    ot ii mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    ot ii mice  (Charles River Laboratories)
    86
    Charles River Laboratories ot ii mice
    OV-BYTE strategy boosts systemic pathogen-specific CD4 + T MEM cell responses (A) Schematic of the experimental design. Congenic CD45.1 + SM CD4 + T cells were adoptively transferred into <t>naive</t> <t>C57BL/6</t> recipients (CD45.2 + ), which were then infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, SM CD4 + T cells in various organs were analyzed. (B and C) Frequency (B) and number (C) of SM CD4 + cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). Quantification of SM CD4 + cells from 100 μL of peripheral blood. (D) Flow cytometry analysis of SM CD4 + T cells on day 15 post-tumor engraftment from the PBS-, NDV-WT-, or NDV-GP-treated group. Numbers adjacent to the outlined areas indicates percentages of SM CD4 + cells among total CD4 + T cells. (E) Schematic of the experimental design. Naive C57BL/6 mice were infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, endogenous LCMV GP 66-77 tetramer + CD4 + T cells in various organs were analyzed. (F and G) Frequency (F) and number (G) of endogenous LCMV GP 66-77 tetramer + CD4 + T cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). (H) Schematic of the experimental design. Congenic CD45.1 <t>+</t> <t>OT-II</t> CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LM-OVA and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, Ad5-WT, or Ad5-OVA daily via the intratumoral route. On day 15 post-tumor engraftment, OT-II CD4 + T cells in various organs were analyzed. (I and J) Frequency (I) and number (J) of OT-II CD4 + cells in the indicated organs of groups administrated PBS (indicated by gray dots), Ad5-WT (indicated by blue dots), or Ad5-OVA (indicated by red dots). All data are representative of at least two independent experiments with at least four mice per group. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA with Turkey’s test (B, C, F, G, I, J). Center values and error bars (B, C, F, G, I, J) indicate mean and SEM.
    Ot Ii Mice, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ot+ii/pm42260178-286-0-5?v=Charles+River+Laboratories
    Average 86 stars, based on 1 article reviews
    ot ii mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    c57bl 6j ot ii mice  (Charles River Laboratories)
    86
    Charles River Laboratories c57bl 6j ot ii mice
    OV-BYTE strategy boosts systemic pathogen-specific CD4 + T MEM cell responses (A) Schematic of the experimental design. Congenic CD45.1 + SM CD4 + T cells were adoptively transferred into <t>naive</t> <t>C57BL/6</t> recipients (CD45.2 + ), which were then infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, SM CD4 + T cells in various organs were analyzed. (B and C) Frequency (B) and number (C) of SM CD4 + cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). Quantification of SM CD4 + cells from 100 μL of peripheral blood. (D) Flow cytometry analysis of SM CD4 + T cells on day 15 post-tumor engraftment from the PBS-, NDV-WT-, or NDV-GP-treated group. Numbers adjacent to the outlined areas indicates percentages of SM CD4 + cells among total CD4 + T cells. (E) Schematic of the experimental design. Naive C57BL/6 mice were infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, endogenous LCMV GP 66-77 tetramer + CD4 + T cells in various organs were analyzed. (F and G) Frequency (F) and number (G) of endogenous LCMV GP 66-77 tetramer + CD4 + T cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). (H) Schematic of the experimental design. Congenic CD45.1 <t>+</t> <t>OT-II</t> CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LM-OVA and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, Ad5-WT, or Ad5-OVA daily via the intratumoral route. On day 15 post-tumor engraftment, OT-II CD4 + T cells in various organs were analyzed. (I and J) Frequency (I) and number (J) of OT-II CD4 + cells in the indicated organs of groups administrated PBS (indicated by gray dots), Ad5-WT (indicated by blue dots), or Ad5-OVA (indicated by red dots). All data are representative of at least two independent experiments with at least four mice per group. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA with Turkey’s test (B, C, F, G, I, J). Center values and error bars (B, C, F, G, I, J) indicate mean and SEM.
    C57bl 6j Ot Ii Mice, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ot+ii/pm41937154-95-0-16?v=Charles+River+Laboratories
    Average 86 stars, based on 1 article reviews
    c57bl 6j ot ii mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    ot ii transgenic mice  (Jackson Laboratory)
    86
    Jackson Laboratory ot ii transgenic mice
    OV-BYTE strategy boosts systemic pathogen-specific CD4 + T MEM cell responses (A) Schematic of the experimental design. Congenic CD45.1 + SM CD4 + T cells were adoptively transferred into <t>naive</t> <t>C57BL/6</t> recipients (CD45.2 + ), which were then infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, SM CD4 + T cells in various organs were analyzed. (B and C) Frequency (B) and number (C) of SM CD4 + cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). Quantification of SM CD4 + cells from 100 μL of peripheral blood. (D) Flow cytometry analysis of SM CD4 + T cells on day 15 post-tumor engraftment from the PBS-, NDV-WT-, or NDV-GP-treated group. Numbers adjacent to the outlined areas indicates percentages of SM CD4 + cells among total CD4 + T cells. (E) Schematic of the experimental design. Naive C57BL/6 mice were infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, endogenous LCMV GP 66-77 tetramer + CD4 + T cells in various organs were analyzed. (F and G) Frequency (F) and number (G) of endogenous LCMV GP 66-77 tetramer + CD4 + T cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). (H) Schematic of the experimental design. Congenic CD45.1 <t>+</t> <t>OT-II</t> CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LM-OVA and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, Ad5-WT, or Ad5-OVA daily via the intratumoral route. On day 15 post-tumor engraftment, OT-II CD4 + T cells in various organs were analyzed. (I and J) Frequency (I) and number (J) of OT-II CD4 + cells in the indicated organs of groups administrated PBS (indicated by gray dots), Ad5-WT (indicated by blue dots), or Ad5-OVA (indicated by red dots). All data are representative of at least two independent experiments with at least four mice per group. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA with Turkey’s test (B, C, F, G, I, J). Center values and error bars (B, C, F, G, I, J) indicate mean and SEM.
    Ot Ii Transgenic Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ot+ii/pm41927540-278-0-6?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    ot ii transgenic mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    OV-BYTE strategy boosts systemic pathogen-specific CD4 + T MEM cell responses (A) Schematic of the experimental design. Congenic CD45.1 + SM CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, SM CD4 + T cells in various organs were analyzed. (B and C) Frequency (B) and number (C) of SM CD4 + cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). Quantification of SM CD4 + cells from 100 μL of peripheral blood. (D) Flow cytometry analysis of SM CD4 + T cells on day 15 post-tumor engraftment from the PBS-, NDV-WT-, or NDV-GP-treated group. Numbers adjacent to the outlined areas indicates percentages of SM CD4 + cells among total CD4 + T cells. (E) Schematic of the experimental design. Naive C57BL/6 mice were infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, endogenous LCMV GP 66-77 tetramer + CD4 + T cells in various organs were analyzed. (F and G) Frequency (F) and number (G) of endogenous LCMV GP 66-77 tetramer + CD4 + T cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). (H) Schematic of the experimental design. Congenic CD45.1 + OT-II CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LM-OVA and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, Ad5-WT, or Ad5-OVA daily via the intratumoral route. On day 15 post-tumor engraftment, OT-II CD4 + T cells in various organs were analyzed. (I and J) Frequency (I) and number (J) of OT-II CD4 + cells in the indicated organs of groups administrated PBS (indicated by gray dots), Ad5-WT (indicated by blue dots), or Ad5-OVA (indicated by red dots). All data are representative of at least two independent experiments with at least four mice per group. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA with Turkey’s test (B, C, F, G, I, J). Center values and error bars (B, C, F, G, I, J) indicate mean and SEM.

    Journal: Molecular Therapy Oncology

    Article Title: Oncolytic virotherapy mobilizes tumor-resident, granzyme B-producing bystander CD4 + T cells to inhibit systemic microbial infection

    doi: 10.1016/j.omton.2026.201187

    Figure Lengend Snippet: OV-BYTE strategy boosts systemic pathogen-specific CD4 + T MEM cell responses (A) Schematic of the experimental design. Congenic CD45.1 + SM CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, SM CD4 + T cells in various organs were analyzed. (B and C) Frequency (B) and number (C) of SM CD4 + cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). Quantification of SM CD4 + cells from 100 μL of peripheral blood. (D) Flow cytometry analysis of SM CD4 + T cells on day 15 post-tumor engraftment from the PBS-, NDV-WT-, or NDV-GP-treated group. Numbers adjacent to the outlined areas indicates percentages of SM CD4 + cells among total CD4 + T cells. (E) Schematic of the experimental design. Naive C57BL/6 mice were infected with LCMV Armstrong and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, NDV-WT, or NDV-GP daily via the intratumoral route. On day 15 post-tumor engraftment, endogenous LCMV GP 66-77 tetramer + CD4 + T cells in various organs were analyzed. (F and G) Frequency (F) and number (G) of endogenous LCMV GP 66-77 tetramer + CD4 + T cells from the indicated organs of groups administrated PBS (indicated by gray dots), NDV-WT (indicated by blue dots), or NDV-GP (indicated by red dots). (H) Schematic of the experimental design. Congenic CD45.1 + OT-II CD4 + T cells were adoptively transferred into naive C57BL/6 recipients (CD45.2 + ), which were then infected with LM-OVA and engrafted with MC38 cells on day 60 post infection. On days 7–12 after tumor engraftment, recipients were administered PBS, Ad5-WT, or Ad5-OVA daily via the intratumoral route. On day 15 post-tumor engraftment, OT-II CD4 + T cells in various organs were analyzed. (I and J) Frequency (I) and number (J) of OT-II CD4 + cells in the indicated organs of groups administrated PBS (indicated by gray dots), Ad5-WT (indicated by blue dots), or Ad5-OVA (indicated by red dots). All data are representative of at least two independent experiments with at least four mice per group. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA with Turkey’s test (B, C, F, G, I, J). Center values and error bars (B, C, F, G, I, J) indicate mean and SEM.

    Article Snippet: C57BL/6, OT-II, and CD45.1 + (B6.SJL- Ptprc a Pepc b /BoyJ) mice were purchased from Jackson Laboratories.

    Techniques: Infection, Flow Cytometry